NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine

Announces Participation in Microdose’s Wonderland: Miami on November 8-9, 2021

NeonMind Biosciences Inc.(CNSX: NEON) (OTCMKTS: NMDBF), an integrated drug development and wellness company, today announced that NeonMind was ranked third in Psychedelia Magazine’s “8 Industry Innovators” segment within the magazine’s inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in bringing psychedelic treatments to patients in need through its anticipated specialty mental health clinic launch and its drug development program for novel obesity treatments.

Separately, Rob Tessarolo, President & CEO of NeonMind, will participate in Microdose’s Wonderland: Miami, the nation’s largest psychedelic medicine business event, which brings together an impressive group of global psychedelic medicine leaders, including scientists and researchers, as well as, investors, entrepreneurs, therapists, patients, and government officials, all championing the growth of the psychedelic medicine industry. Mr. Tessarolo will be participating in one-on-one meetings during the event.

We are honored to be ranked as a top industry innovator in Psychedelia Magazine, which is a testament to our strategy of pursuing unique modalities across the psychedelic treatment spectrum. As we are advancing quickly across our drug development program and planned specialty clinics launch, we look forward to sharing our updates with industry participants at the Wonderland event in Miami.

Robert Tessarolo, President & CEO of NeonMind

Wonderland: Miami will be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 8-9, 2021.

For more information regarding the event or to schedule a one-on-one meeting with management, please contact KCSA Strategic Communications at [email protected].

To view the original press release in its entirety click here